<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03677648</url>
  </required_header>
  <id_info>
    <org_study_id>RSJ10201</org_study_id>
    <nct_id>NCT03677648</nct_id>
  </id_info>
  <brief_title>A Phase II Study in Patients With Moderate to Severe Active Crohn's Disease</brief_title>
  <official_title>A Phase II Randomized, Placebo Controlled, Double-blind, Four Arms Dose-ranging Study to Evaluate the Efficacy and Safety of SHR0302 Compared to Placebo in Patients With Moderate to Severe Active Crohn's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Reistone Biopharma Company Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Reistone Biopharma Company Limited</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The proposed study is a randomized, double-blind, placebo-controlled, multi-center Phase II
      study to investigate the safety and efficacy of SHR0302 in patients with moderate to severe
      active Crohn's Disease. The study aims to evaluate the optimal dose of SHR0302 and time
      needed in inducing clinical remission in active CD. This is an 12+12 weeks study, in which
      participants who complete the first 12 weeks treatment phase, will have the option to enter a
      blinded active arms 12-week extension phase. Early withdrawn subjects during the first
      treatment phase cannot enter the extension phase. The total duration of the study
      participation, including extension and follow-up, will be approximately 26 weeks.

      With the wealth of scientific evidence on JAK/STAT involvement in IBD, the data from similar
      class of new drugs and the current data on SHR0302 (JAK1 inhibitor), support the rationale to
      proceed with phase II studies to evaluate the efficacy and safety of SHR0302 in patients with
      moderate to severe active CD.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 28, 2018</start_date>
  <completion_date type="Anticipated">August 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">May 26, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The percentage of subjects achieving clinical remission at week 12.</measure>
    <time_frame>week12</time_frame>
    <description>The percentage of subjects achieving clinical remission at week 12, defined as Crohn's Disease Activity Index (CDAI) score &lt; 150.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The percentage of subjects achieving clinical remission defined as mean daily stool frequency (SF) ≤2.5, and abdominal pain (AP) ≤ 1 using the Patient Reported Outcome from CDAI at week 1, 4, 8, 12, 13, 16, and 24.</measure>
    <time_frame>week 1, 4, 8, 12, 13, 16, and 24</time_frame>
    <description>The percentage of subjects achieving clinical remission defined as mean daily stool frequency (SF) ≤2.5, and abdominal pain (AP) ≤ 1 using the Patient Reported Outcome from CDAI at week 1, 4, 8, 12, 13, 16, and 24.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage of subjects achieving clinical remission defined as PRO2 &lt; 8 at week 1, 4, 8, 12, 13, 16, and 24.</measure>
    <time_frame>week 1, 4, 8, 12, 13, 16, and 24</time_frame>
    <description>The percentage of subjects achieving clinical remission defined as PRO2 &lt; 8 at week 1, 4, 8, 12, 13, 16, and 24.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage of subjects achieving clinical response defined as a CDAI decrease from baseline of ≥ 100 points at week 1, 4, 8, 12, 13, 16, and 24.</measure>
    <time_frame>week 1, 4, 8, 12, 13, 16, and 24</time_frame>
    <description>The percentage of subjects achieving clinical response defined as a CDAI decrease from baseline of ≥ 100 points at week 1, 4, 8, 12, 13, 16, and 24.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">144</enrollment>
  <condition>Crohn's Disease</condition>
  <arm_group>
    <arm_group_label>SHR0302 dose A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants randomized in this arm will receive dose A of SHR0302 until end of study at week 24.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SHR0302 dose B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants randomized in this arm will receive dose B of SHR0302 until end of study at week 24.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SHR0302 dose C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants randomized in this arm will receive dose C of SHR0302 until end of study at week 24.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants randomized in this arm will receive placebo until week 12, and then will be re-randomized into one of the 3 active arms (dose A, dose B, and dose C of SHR0302) in a 1:1:1 allocation ratio until the end of study at week 24.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHR0302</intervention_name>
    <description>The study drug, SHR0302, is designed to block the activity of an enzyme protein called JAK (known as a JAK inhibitor).</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>SHR0302 dose A</arm_group_label>
    <arm_group_label>SHR0302 dose B</arm_group_label>
    <arm_group_label>SHR0302 dose C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>Placebos</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and Female subject at ≥18 and ≤ 75 years of age at randomization.

          -  Subjects with a documented three-month history of diagnosed ileal, colonic, or
             ileocolonic Crohn's Disease at the time of randomization.

          -  Currently having Crohn's Disease with Crohn's Disease Activity Index (CDAI) score ≥
             220 to ≤450.

        Exclusion Criteria:

          -  Diagnosis of indeterminate colitis, or clinical findings suggestive of Ulcerative
             Colitis.

          -  Subject with CD with stoma, gastric or ileoanal pouch, proto-colectomy or total
             colectomy, symptomatic stenosis or stricture, history of bowel perforation, suspected
             abscess; actively draining fistula.

          -  Treatment naïve subjects diagnosed with Crohn's disease, (without previous exposure to
             treatment).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Weiss</last_name>
    <role>Principal Investigator</role>
    <affiliation>West Central Gastro Florida</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Awad Amir</last_name>
    <role>Principal Investigator</role>
    <affiliation>West Central Gastro Florida</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Capozza Thomas</last_name>
    <role>Principal Investigator</role>
    <affiliation>NECCR Primacare Research, LLC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mahesh Allam</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wellness Clinical Research, LLLC-Central Florida</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Stokesberry</last_name>
    <role>Principal Investigator</role>
    <affiliation>Digestive Disease Specialists, Inc</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Max Zhang</last_name>
    <phone>+8618662156927</phone>
    <email>max.zhang@reistonebio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>West Central Gastroenterology d/b/a Gastro Florida</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33756</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael L Weiss</last_name>
    </contact>
    <investigator>
      <last_name>Michael Weiss</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wellness Clinical Research, LLLC-Central Florida</name>
      <address>
        <city>Lake Wales</city>
        <state>Florida</state>
        <zip>33853</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Allam Mahesh</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>West Central Gastroenterology d/b/a Gastro Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33626</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Awad Amir</last_name>
    </contact>
    <investigator>
      <last_name>Awad Amir</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NECCR Primacare Research, LLC</name>
      <address>
        <city>Fall River</city>
        <state>Massachusetts</state>
        <zip>02721</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Capozza Thomas</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wilmington Health</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mathew Mlot, MD</last_name>
      <phone>910-341-1321</phone>
      <phone_ext>1,2,3</phone_ext>
      <email>mmlot@wilmingtonhealth.com</email>
    </contact>
    <contact_backup>
      <last_name>Arielle Lapid</last_name>
      <phone>910.341.1321</phone>
      <phone_ext>1,2,3,4</phone_ext>
      <email>Arielle.Lapid@qcareresearch.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Digestive Disease Specialists, Inc.</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stokesberry David</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Guangdong Provincial People's Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Weihong Sha</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital, Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Baili Chen</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Henan Provincial People's Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiuling Li</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wuxi People's Hospital</name>
      <address>
        <city>Wuxi</city>
        <state>Jiangsu</state>
        <zip>214023</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qiang Zhan</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yangzhou First People's Hospital</name>
      <address>
        <city>Yangzhou</city>
        <state>Jiangsu</state>
        <zip>225001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yanbing Ding</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Indywidualma Specjalistyczna Praktyka Lekarska Maciej Zymla</name>
      <address>
        <city>Knurów</city>
        <zip>44-190</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zymla Maciej</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>SOLUMED Centrum Medyczne</name>
      <address>
        <city>Poznań</city>
        <zip>60-529</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marek Karczewski</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>KO-MED Central Kliniczne Plulawy</name>
      <address>
        <city>Puławy</city>
        <zip>24-100</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wolanski Lukasz</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gabinet Lekarski Bartosz Korczowski</name>
      <address>
        <city>Rzeszów</city>
        <zip>35-302</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bartosz Korczowski</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Specjalistyczna Praktyka Lekarska dr med. Marek Horynski</name>
      <address>
        <city>Sopot</city>
        <zip>81-756</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dariusz Kleczkowski</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>KO-MED Centra Kliniczne Staszow</name>
      <address>
        <city>Staszów</city>
        <zip>28-200</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jacek Kieltucki</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centrum Zdrowia MDM</name>
      <address>
        <city>Warszawa</city>
        <zip>00-635</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jaroslaw Kierkus</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nzoz Vivamed</name>
      <address>
        <city>Warszawa</city>
        <zip>03-580</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>PlanetMed sp. z o.o.</name>
      <address>
        <city>Wrocław</city>
        <zip>53-333</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Barbara Wozniak-Stolarska</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Amicare Sp. z o.o. Sp.k</name>
      <address>
        <city>Łódź</city>
        <zip>90-644</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rafal Drozda</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>SALVE Zakład Opieki Zdrowotnej Sp. zo.o.</name>
      <address>
        <city>Łódź</city>
        <zip>91-211</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bartosz Lesniowski</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>EZ-MED Centrum Medyczne</name>
      <address>
        <city>Świdnica</city>
        <zip>58-100</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Witold Marczynski</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>RCI Chernivtsi Regional Clinical Hospital Dept of Gastroenterology Bukovinsky SMU</name>
      <address>
        <city>Chernivtsi</city>
        <zip>58002</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Oleksandr Fediv</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>I.I.Mechnykov Dnipropetrovsk Regional Clinical Hospital</name>
      <address>
        <city>Dnipro</city>
        <zip>49005</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Olha Khodasenko</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHI Kharkiv City Clinical Hospital #13</name>
      <address>
        <city>Kharkiv</city>
        <zip>61124</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Viktoriia Reznikova</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Communal City Clinical Hospital of Ambulance, Dept of Therapy #1 D.Halytskyi Lviv NMU</name>
      <address>
        <city>Lviv</city>
        <zip>79059</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Valeriy Vdovychenko</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CCH #1 Vinnytsia M.I. Pyrogov NMU Ch of Propaedeutics of IM</name>
      <address>
        <city>Vinnytsia</city>
        <zip>21029</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Halyna Tomashkevych</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Communal Institution Center of the Primary Medical- Sanitary Care#2</name>
      <address>
        <city>Vinnytsia</city>
        <zip>21050</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Viacheslav Chernobrovyi</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>O.F. Herbachevskiyi Zhytomyr Regional Clinical Hospital</name>
      <address>
        <city>Zhytomyr</city>
        <zip>10002</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yuriy Bilotskyi</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
    <country>Poland</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>September 17, 2018</study_first_submitted>
  <study_first_submitted_qc>September 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 19, 2018</study_first_posted>
  <last_update_submitted>September 26, 2019</last_update_submitted>
  <last_update_submitted_qc>September 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

